IBRX — Immunitybio Income Statement
0.000.00%
Last trade - 00:00
- $4.95bn
- $5.53bn
- $0.62m
- 11
- 11
- 100
- 36
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.2 | 0.605 | 0.934 | 0.24 | 0.622 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 158 | 221 | 331 | 352 | 363 |
Operating Profit | -156 | -221 | -330 | -351 | -362 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -160 | -226 | -350 | -417 | -584 |
Provision for Income Taxes | |||||
Net Income After Taxes | -160 | -224 | -350 | -417 | -584 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -158 | -222 | -347 | -417 | -583 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -158 | -222 | -347 | -417 | -583 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.431 | -0.57 | -0.891 | -1.04 | -1.14 |